Vincerx Pharma (VINC) Proxy Filing summary

Executive summary

• Special Meeting called to vote on liquidation and dissolution under Delaware law, following failed capital raises, unsuccessful merger attempts, and inability to secure strategic alternatives.

• Board determined dissolution is in the best interests of stakeholders after reviewing financial condition, lack of revenue, and inability to maintain Nasdaq listing.

• If approved, company will wind up affairs, liquidate assets, pay obligations, and distribute any remaining assets, though distributions to stockholders are not expected.

• Board retains discretion to abandon or amend the dissolution if circumstances change.

Voting matters and shareholder proposals

• Two proposals: (1) approve liquidation and dissolution; (2) adjourn meeting if more time is needed to solicit votes.

• Board recommends voting FOR both proposals.

• No other business is expected at the meeting.

• No appraisal rights for stockholders under Delaware law.

• If dissolution is approved, no future annual meetings are planned.

Board of directors and corporate governance

• Board authorized and adopted the Plan of Liquidation on April 17, 2025, after extensive review of alternatives.

• Board considered risks, including potential for no distributions, unanticipated delays, and possible stockholder liability for unresolved claims.

• Board may appoint officers, consultants, and liquidating trustees to oversee the wind-down.

• Board and officers may receive additional compensation for efforts related to the dissolution.